Seegene rolls out COVID-19 mutant identification test
March 2021—Seegene announced it has developed the first COVID-19 diagnostic variant test capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Euroimmun launches COVID-19 PCR, ELISA tests
February 2021—Euroimmun launched its CE-marked EuroRealTime SARS-CoV-2/Influenza A/B, which detects and differentiates genetic material from SARS-CoV-2 and influenza virus types A and B using throat swab samples of patients with acute symptoms, which can be indicative of COVID-19 or flu. The assay is compatible with common real-time PCR thermal cyclers and is available in countries that accept the CE mark. The EuroRealTime analysis software allows for standardized evaluation of test results. The company also launched its CE-marked SARS-CoV-2 Antigen ELISA, a laboratory diagnostic test for the direct detection of SARS-CoV-2 by semiquantitative determination of the virus-specific nucleocapsid protein in swab samples from the upper respiratory tract. Validation data revealed 93.6 percent sensitivity and 100 percent specificity as compared with real-time PCR tests. The assay can be automatically processed on all open ELISA platforms and is available in countries that recognize the CE mark.
Tecan automated whole blood processing system
February 2021—Tecan has launched the Fluent Mix and Pierce Workstation to provide end-to-end automation for whole blood pipetting in clinical environments.
Randox SARS-CoV-2 antibody control
February 2021—Randox introduced its Acusera SARS-CoV-2 Antibody Control with reactive and nonreactive controls for anti SARS-CoV-2 to support assay validation and routine performance monitoring of serological assays for COVID-19. The third-party control is supplied in a liquid, ready-to-use format with a 30-day open vial stability at 2° to 8°C.
Bio-Rad unveils online resource for immunoblotting
February 2021—Bio-Rad Laboratories launched an online library called Bio-Rad Western Blotting Learning Center. The center was created to provide researchers an online platform to learn about western blotting and offers information on the science of western blotting, best practices, tips and techniques, as well as guidance on how to troubleshoot experiments. It is available via the company’s website at bio-rad.com/LearnWestern.
OGT expands NGS cancer panel offering
February 2021—Oxford Gene Technology has expanded its SureSeq range of next-generation sequencing panels to include a comprehensive myeloid panel and a breast and ovarian cancer panel that incorporate copy number variation detection.
FDA authorizes at-home COVID-19 test
February 2021—The FDA issued an emergency use authorization to Lucira Health for its COVID-19 All-In-One Test Kit, the first COVID-19 diagnostic test for self-testing at home and that provides rapid results.
Beckman’s $4, high-throughput COVID-19 antigen test
February 2021—Beckman Coulter launched the Access SARS-CoV-2 Antigen assay, a high-throughput COVID-19 test available in the U.S., priced at $4 to health care providers, including public and private institutions, governments, and nonprofits.
DiaSorin gets additional BARDA funding
February 2021—DiaSorin Molecular received additional federal funding from the Biomedical Advanced Research and Development Authority for the validation and submission of the Simplexa COVID-19 Direct kit and the Simplexa COVID-19 & Flu A/B Direct kit for FDA 510(k) clearance. The company initially received BARDA funding in March 2020 to test, validate, and submit the Simplexa COVID-19 Direct kit for FDA emergency use authorization.
PerkinElmer acquires Horizon, gets EUA for sample pooling
February 2021—PerkinElmer and Horizon Discovery have reached an agreement in which PerkinElmer will acquire Horizon for about $383 million.